The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer.
Abstract
We performed an escalating dose study of the combined administration of interleukin-2 (IL-2) and alpha-interferon (alpha-IFN) in 94 patients with metastatic cancer. Patients received alpha-IFN at a dose of 3 x 10(6) U/m2 in conjunction with IL-2 at doses of either 1 x 10(6) U/m2 (six patients), 3 x 10(6) U/m2 (32 patients), or 4.5 x 10(6) U/m2 (26 patients). Thirty patients received alpha-IFN at 6 x 10(6) U/m2 plus IL-2 at 4.5 x 10(6) U/m2. Patients each received cytokine as an intravenous bolus infusion every 8 hours for up to 5 consecutive days and after a 10-day rest received a second cycle of combination cytokines. Of the 91 patients evaluable for response, seven patients had a complete regression of cancer, and 18 had a partial regression. At the four increasing dose levels used in patients with renal cell cancer (35 patients) or melanoma (39 patients), objective responses were seen in 17% (of six patients), 24% (of 25 patients), 38% (of 16 patients), and 41% (of 27 patients), respectively. Of the 25 total responding patients, 16 are still responding 5 to 14 months after treatment. The toxicities associated with the combined administration of IL-2 and alpha-IFN were similar to those expected from each agent alone. There was one treatment-related death in the 94 patients treated in this study. Thus, using increasing doses of the combination of IL-2 and alpha-IFN, it appears that response rates may be related to the doses of the cytokines used, and that at the highest doses of these combination cytokines, response rates may be higher than those for either cytokine alone. A prospective randomized trial comparing the cytokine combinations with each cytokine administered alone is necessary as is the extension of this combination cytokine treatment to patients with other types of solid cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Virus interference. I. the interferon
Isaacs, A., & Lindenmann, J. (1957) · Proceedings of the Royal Society of London. Series B - Biological Sciences · doi:10.1098/rspb.1957.0048 · Cited by 3,451
Rosenberg, S. A., Lotze, M. T., Muul, L. M., Chang, A. E., Avis, F. P., Leitman, S., Linehan, W. M., Robertson, C. N., Lee, R. E., Rubin, J. T., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198704093161501 · Cited by 2,735
Self-citationInterleukin-2: Inception, Impact, and Implications
Smith, K. A. (1988) · Science · doi:10.1126/science.3131876 · Cited by 2,153
A New Approach to the Adoptive Immunotherapy of Cancer with Tumor-Infiltrating Lymphocytes
Rosenberg, S. A., Spiess, P., & Lafreniere, R. (1986) · Science · doi:10.1126/science.3489291 · Cited by 1,880
Self-citationRosenberg, S. A., Mulé, J. J., Spiess, P. J., Reichert, C. M., & Schwarz, S. L. (1985) · The Journal of experimental medicine · doi:10.1084/jem.161.5.1169 · Cited by 745
Self-citationMulé, J. J., Shu, S., Schwarz, S. L., & Rosenberg, S. A. (1984) · Science · doi:10.1126/science.6332379 · Cited by 688
Self-citationBiological Activity of Recombinant Human Interleukin-2 Produced in Escherichia coli
Rosenberg, S. A., Grimm, E. A., McGrogan, M., Doyle, M., Kawasaki, E., Koths, K., & Mark, D. F. (1984) · Science · doi:10.1126/science.6367046 · Cited by 595
Self-citationLotze, M. T. (1986) · JAMA · doi:10.1001/jama.1986.03380220083027 · Cited by 455
Self-citationLafrenière, R., & Rosenberg, S. A. (1985) · PubMed · Cited by 380
Self-citationCheever, M. A., Greenberg, P. D., Fefer, A., & Gillis, S. (1982) · The Journal of experimental medicine · doi:10.1084/jem.155.4.968 · Cited by 265
In Vivo Antitumor Activity of Tumor-Infiltrating Lymphocytes Expanded in Recombinant Interleukin-2
(1987) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/79.5.1067 · Cited by 258
Recombinant Interferon Enhances Monoclonal Antibody-Targeting of Carcinoma Lesions in Vivo
Greiner, J. W., Guadagni, F., Noguchi, P., Pestka, S., Colcher, D., Fisher, P. B., & Schlom, J. (1987) · Science · doi:10.1126/science.3580039 · Cited by 174
Cameron, R. B., McIntosh, J. K., & Rosenberg, S. A. (1988) · PubMed · Cited by 153
Self-citationvan den Berg, H., Leahey, W., Lynch, M., Clarke, R. C., & Nelson, J. (1987) · British Journal of Cancer · doi:10.1038/bjc.1987.49 · Cited by 86
Talmadge, J. E., Herberman, R. B., Chirigos, M. A., Maluish, A. E., Schneider, M., Adams, J. S., Philips, H., Thurman, G. B., Varesio, L., Long, C., et al. (1985) · The Journal of Immunology · doi:10.4049/jimmunol.135.4.2483 · Cited by 85
Induction of major histocompatibility class I antigens by interferons in undifferentiated F9 cells
Wan, Y. Y., Orrison, B. M., Lieberman, R., Lazarovici, P., & Ozato, K. (1987) · Journal of Cellular Physiology · doi:10.1002/jcp.1041300214 · Cited by 40
Enhancement of Fcγ receptor expression in interferontreated mice
Aguet, M., Vignaux, F., Fridman, W. H., & Gresser, I. (1981) · European Journal of Immunology · doi:10.1002/eji.1830111114 · Cited by 27
Cited by
High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal
Lotze, M. T., & Tracey, K. J. (2005) · Nature Reviews Immunology · doi:10.1038/nri1594 · Cited by 2,487
Self-citationFunctional Nanomaterials for Phototherapies of Cancer
Cheng, L., Wang, C., Feng, L., Yang, K., & Liu, Z. (2014) · Chemical Reviews · doi:10.1021/cr400532z · Cited by 2,425
Menetrier-Caux, C., Montmain, G., Dieu, M. C., Bain, C., Favrot, M. C., Caux, C., & Blay, J. Y. (1998) · Blood · doi:10.1182/blood.v92.12.4778 · Cited by 590
“The increased proliferation induced by RCC CM was found to be mediated by M-CSF because (1) anti–M-CSF, but not anti–IL-6/IL-6R, reversed this effect and (2) recombinant M-CSF, but not recombinant IL-6, exerted a similar proliferative effect (not shown).”
BackgroundThe Interferons: Mechanisms of Action and Clinical Applications
Baron, S. (1991) · JAMA · doi:10.1001/jama.1991.03470100067035 · Cited by 392
Klapper, J. A., Downey, S. G., Smith, F. O., Yang, J. C., Hughes, M. S., Kammula, U. S., Sherry, R. M., Royal, R. E., Steinberg, S. M., & Rosenberg, S. (2008) · Cancer · doi:10.1002/cncr.23552 · Cited by 434
Self-citation
Metadata
- Authors
- Rosenberg, S. A., Lotze, M. T., Yang, J. C., Linehan, W. M., Seipp, C., Calabro, S., Karp, S. E., Sherry, R. M., Steinberg, S., & White, D. E.
- Venue
- Journal of Clinical Oncology
- Published
- 1989-12
- Volume
- 7
- Issue
- 12
- Pages
- 1863-1874
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2285002277
- Cited by
- 374
- References
- 17
- FWCI
- 14.07
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.